The short version of Hepatocyte growth factor fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-02-26. Anything still debated is marked as such rather than presented as settled.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Typical supplied form | Lyophilized powder | Stored desiccated before use |
| Recommended storage | -20 °C | Protect from light and moisture |
| Common stock solvent | Dimethyl sulfoxide | Aqueous solubility may be limited |
| Purity method | Reverse-phase HPLC | Reports percent purity and impurities |
| Identity method | Mass spectrometry | Confirms molecular mass |
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
The proposed mechanism of dihexa involves activation of hepatocyte growth factor and its receptor, c-Met. In cell models, this signaling pathway is associated with dendritic spine formation and synaptic reorganization. Dihexa is described as a stabilized analog of angiotensin IV, which also interacts with related systems. However, the precise binding profile and downstream effects remain incompletely characterized. Most mechanistic evidence comes from in vitro assays and rodent studies rather than human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Chitosan is a linear polysaccharide composed of randomly distributed β-(1→4)-linked D-glucosamine (deacetylated unit) and N-acetyl-D-glucosamine (acetylated unit). It is made by treating the chitin shells of shrimp and other crustaceans with an alkaline substance, such as sodium hydroxide. Chitosan has a number of commercial and possible biomedical uses. It can be used in agriculture as a seed treatment and biopesticide, helping plants to fight off fungal infections. In winemaking, it can be used as a fining agent, also helping to prevent spoilage. In industry, it can be used in a self-healing polyurethane paint coating. In medicine, it is useful in bandages (in the form of chitosan hydrocolloid dressing) to reduce bleeding and as an antibacterial agent; it can also be used to help deliver drugs through the skin.
== Clinical significance == Recessive mutations in NADK2 cause NADK2 deficiency, an inherited metabolic disorder characterized by neurological symptoms including hypotonia, developmental delay, ataxia, and encephalopathy. Affected individuals also show metabolic abnormalities, including hyperlysinemia and impaired fat oxidation with elevated C10:2-carnitine levels, consistent with secondary 2,4-dienoyl-CoA reductase deficiency. Cancer cells are exposed to elevated oxidative stress and are consequently highly dependent on mitochondrial NADPH to maintain redox homeostasis. NADK2 is essential for mitochondrial NADPH production and has therefore been proposed as a potential target to increase oxidative stress and sensitize cancer cells to apoptosis. A lack of NADK2 additionally impairs proline biosynthesis, rendering cancer cells dependent on exogenous proline for proliferation. NADK2 has been linked to Alzheimer's disease. Tau oligomers upregulate NADK2 in human neurons, leading to increased mitochondrial NADPH production, which in turn increases LRP1 expression and promotes tau uptake, creating a self-reinforcing cycle.
== Side effects == The most concerning side effects, as with other aminoglycosides, are kidney toxicity and ear toxicity. Transient or permanent deafness may result. The vestibular portion of cranial nerve VIII (the vestibulocochlear nerve) can be affected, resulting in tinnitus, vertigo, ataxia, kidney toxicity, and can potentially interfere with diagnosis of kidney malfunction. Common side effects include vertigo, vomiting, numbness of the face, fever, and rash. Fever and rashes may result from persistent use. Use is not recommended during pregnancy. Congenital deafness has been reported in children whose mothers received streptomycin during pregnancy. Use appears to be okay while breastfeeding. It is not recommended in people with myasthenia gravis.
Sources: en.wikipedia.org
Organic cages function as molecular containers through specific host-guest interactions. The defined cavity can encapsulate guest molecules of appropriate size and chemical compatibility. The binding process often induces measurable changes in cage properties, enabling their use as molecular sensors. Selective binding of specific analytes can trigger optical, electronic, or structural responses that provide detection signals. These features enable applications in environmental monitoring and chemical detection. The host-guest chemistry extends to selective capture of environmental pollutants and valuable chemicals. The tunable cavity size and surface chemistry allow targeting specific molecules, while some cages demonstrate stimuli-responsive guest release for controlled delivery applications.
== Pharmacodynamics == CPA has antiandrogenic activity, progestogenic activity, weak partial glucocorticoid activity, weak steroidogenesis inhibitor activity, and agonist activity at the pregnane X receptor. It has no estrogenic or antimineralocorticoid activity. In terms of potency, CPA is described as a highly potent progestogen, a moderately potent antiandrogen, and a weak glucocorticoid.
== Select publications == Masur, S.K. (1969). "Fine structure of the autotransplanted pituitary of the red eft. Notophthalmus viridescens". Gen. Comp. Endocrin. 12: 12–32. Masur, S.K.; Holtzman, E.; Schwartz, I.L.; Walter, R. (1971). "Correlation between pinocytosis and hydroosmosis induced by neurohypophyseal hormone and mediated by adenosine 3', 5'-cyclic monophosphate". J. Cell Biol. 49: 582–589. Masur, S.K.; Dewal, H.S.; Dinh, T.T.; Erenburg, I.; Petridou, S. (1996). "Myofibroblasts differentiate from fibroblasts plated at low density". Proc. Natl. Acad. Sci. 93: 4219–4223. Maltseva, O; Folger, P; Zekaria, D; Petridou, S; Masur, SK (2001). "Fibroblast growth factor reversal of the corneal myofibroblast phenotype". Invest Ophthalmol Vis Sci. 42: 2490–5. PMID 11581188.. Masur, S.; Kane, C. M. (2001-12-21). "Tapping science's women for the podium". Science. 294 (5551): 2480. doi:10.1126/science.294.5551.2480a. ISSN 0036-8075. PMID 11770518.. Bernstein, AM; Twining, SS; Warejcka, DJ; Tall, E; Masur, SK (2007). "Urokinase receptor cleavage: a crucial step in fibroblast-to-myofibroblast differentiation". Mol Biol Cell. 18: 2716–27. doi:10.1091/mbc.e06-10-0912. PMC 1924808. PMID 17507651.. Masur, Sandra Kazahn (January 2013). "Women in cell biology: a seat at the table and a place at the podium". Molecular Biology of the Cell. 24 (2): 57–60. doi:10.1091/mbc.E12-07-0517. ISSN 1939-4586. PMC 3541963. PMID 23307103.. Masur, Sandra K. (2015-08-01). "Invisible woman?". Trends in Cell Biology. 25 (8): 437–439. doi:10.1016/j.tcb.2015.06.001. ISSN 0962-8924.
Sources: en.wikipedia.org
Typical storage is at -20 °C in a desiccated container protected from light. Repeated freeze-thaw cycles are usually minimized to reduce degradation. Specific conditions should follow the supplier’s documentation.
Mass spectrometry is commonly used to confirm molecular mass, while reverse-phase HPLC assesses purity. Some laboratories also use nuclear magnetic resonance for structural verification. These methods are standard for research peptides.
Aqueous solubility can be limited and varies by batch and salt form. Dimethyl sulfoxide is often used for stock solutions. Supplier documentation or a solubility test can clarify behavior for a given lot.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.